1. What is it?
Selank is a seven-amino-acid peptide: a short chain with a specific sequence. It was developed as an analogue of tuftsin, a natural peptide involved in immune processes. This similarity does not mean Selank acts only on immunity. Research has mainly focused on anxiety and nervous-system function. TP-7 also refers to Selank; N-acetyl indicates an actual molecular modification. [104] [103] [105]
2. Why do people turn to it?
People seek Selank hoping for less tension, calmer responses to stress and sometimes better concentration. Studies in anxiety disorders come closest to these expectations. They do not show that every episode of workplace stress needs this substance or that it improves healthy people's mental performance. Claims of nootropic, or thinking-supporting, action must be separated from reliably measured, lasting improvements in everyday memory. [98] [99]
3. How does it work?
One research area concerns GABA, which carries inhibitory signals in the nervous system. In brain-cell membrane preparations, Selank changed GABA binding to its receptor. This suggests a possible mechanism, not identical action to a known sedative or safe combinations with other substances. Laboratory findings do not yet establish strength, duration or risk in humans. [101]
4. What do studies actually show?
In a 2008 study, 30 patients with generalized anxiety disorder or neurasthenia received Selank. Neurasthenia covers symptoms including exhaustion and tension. The authors reported reduced anxiety symptoms. A comparative article from 2014 also described favourable results. However, available English abstracts do not adequately explain all safeguards against misleading treatment assessment. Without full details, it is difficult to judge the certainty of the findings or whether other teams would obtain the same effect. [98] [99]
5. What do we still not know?
A 2015 study examined Selank combined with phenazepam. It therefore cannot establish that all the reported benefits would occur with the peptide alone. A 2020 brain-imaging study in healthy participants assessed short-term changes in how brain regions work together. It did not test long-term treatment of memory disorders. These examples show why the phrase studied in humans needs an explanation of exactly what was studied and what was actually found. [100] [102]
6. What are the risks?
Small studies cannot rule out rare side effects, potential dependence or problems with long-term combinations with other medicines. Even if authors report good tolerability in their group, this does not guarantee it for everyone. Laboratory interactions with the GABA system support the need for careful interaction studies, but do not let us predict those interactions ourselves. Nor is there a basis for automatically applying ordinary Selank's safety findings to modified forms or any route of administration. [98] [100] [101]
7. Is it an approved medicine?
The sources checked for this profile did not confirm an approved indication for Selank to treat anxiety in Poland. The presence of its name in an FDA database does not change that status: a UNII record identifies a substance, and the FDA explicitly states that an identifier does not mean a medicine is approved. Publication of a study conducted in another country is not Polish marketing authorisation either. Selank's profile should therefore be read as an assessment of limited evidence, not a list of approved uses. [104] [98]
8. What is new in research?
By 3 November 2026, no new large clinical trial had been found that resolved the main uncertainties about Selank. One of the later primary studies, published in 2022, concerned reducing morphine withdrawal symptoms in rats. This is a different field and level of evidence from treating anxiety in humans. It should not be presented as confirmation of addiction treatment in patients or as a new publication from the current year. [103] [98]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
2008; primary study in patients with anxiety disorders; Russian article, English abstract; details of randomisation and blinding could not be established from the abstract; PubMed metadata and English abstract reviewed, not the full text. Accessed: 3 November 2026.
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
2018; primary receptor study using brain-cell membrane preparations; findings not applied to human drug-combination safety; PubMed metadata and English abstract reviewed, not full text · DOI: 10.2174/0929866525666180925144642. Accessed: 3 November 2026.
- [Optimization of the treatment of anxiety disorders with selank]
2015; primary study of Selank combined with phenazepam; Russian article, English abstract read; PubMed metadata and English abstract read, without the full text · DOI: 10.17116/jnevro20151156133-40. Accessed: 03.11.2026.
- N-Acetyl selank
Primary chemical identity record in NIH PubChem, CID 133082488, using FDA GSRS data; record modified on 5 September 2026. The sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH, formula and data provenance were reviewed; no clinical data. The direct FDA GSRS page J3PM702O93 did not return readable content. Accessed: 3 November 2026.
- SELANK
FDA Substance Registration System; name, sequence, identifier and the statement that a UNII does not mean drug approval reviewed. Accessed: 3 November 2026.
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.
Online 2 November 2022; October 2022 issue; primary experiment in morphine-dependent rats; PubMed metadata and English abstract reviewed, not the full text · DOI: 10.1007/s10517-022-05624-x. Accessed: 3 November 2026.
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
2014; primary comparative study in patients with anxiety disorders; Russian article, English abstract; PubMed metadata and English abstract reviewed, not full text. Accessed: 3 November 2026.
- Functional Connectomic Approach to Studying Selank and Semax Effects
Online 27 April 2020; January 2020 issue; primary short brain-imaging study in healthy people; Selank and Semax studied as separate interventions; PubMed metadata and English abstract reviewed, not the full text · DOI: 10.1134/S001249662001007X. Accessed: 3 November 2026.